Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by SanFrancisco99on Jul 05, 2014 1:51pm
299 Views
Post# 22718437

Other Deals

Other DealsQuestion:  Is there anything in this proposal from Citibank/Eastern that would prevent a pharma (or other interested parties) from making an offer at any time for RVX (including in the period between today and the vote date in August)?

My guess is that this possibility is still open.

In my estimation, the Citibank/Eastern arrangement and the share purchases by officers/directors are a strong sign that pharma sees value here... and that a deal after RE-MACE has a high likelihood.

Might this also mean that a deal before then is also a possibility?  Do we have any evidence that might rule that out?  I don't think so.

So there still may be the potential for a deal at any time.  Perhaps this arrangement is intended (in part) to smoke out any potential offers out there.  Any pharma kicking our tires must know now that RVX is in a strong negotiating position.

That strong negotiating position is in both the near-term and the longer term.  

IMHO.  DYODD.







Bullboard Posts